<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="global pandemic. Abstract Coronavirus disease 2019 (COVID-19) is a pandemic" exact="infection" post="caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)."/>
 <result pre="clinical trial searching for an effective Coronavirus disease 2019 (COVID-19)" exact="treatment" post="launched by the World Health Organization and its partners"/>
 <result pre="potentially effective regimens [9]. It has been approved for the" exact="treatment" post="of Ebola, respiratory syncytial virus (RSV), Junin virus, Lassa"/>
 <result pre="an analog of the peptide chain substrate approved for the" exact="treatment" post="of HIV, has the potential to prevent the pro-form"/>
 <result pre="Kaletra, was approved in USA in 2000 to treat HIV" exact="infection" post="[20]. With the capability to inhibit the protease of"/>
 <result pre="an RNA-dependent RNA polymerase inhibitor and is approved for the" exact="treatment" post="of RSV and HCV [37]. Although ribavirin was recommended"/>
 <result pre="RSV and HCV [37]. Although ribavirin was recommended for COVID-19" exact="treatment" post="according to Chinese guidelines, it lacks solid evidence [38]."/>
 <result pre="leading to muscle paralysis [41]. It is approved for the" exact="treatment" post="of head lice, scabies, strongyloidiasis, trichuriasis, ascariasis, and lymphatic"/>
 <result pre="have revealed a potential role of importin Î±/Î² 1 during" exact="infection" post="[45]. Nuclear transport of viral proteins is essential for"/>
 <result pre="[45]. An in vitro study showed that a single ivermectin" exact="treatment" post="reduced SARS-CoV-2 by 5000-fold at 48Â h in cell"/>
 <result pre="glycosylation of its cellular receptor ACE2 [51]. Recent in vitro" exact="testing" post="revealed its ability to effectively reduce the viral copy"/>
 <result pre="to 54 cases developing cardiovascular complications post-hydroxychloroquine use for the" exact="treatment" post="of COVID-19 [57]. Tocilizumab Mechanisms The rapid development of"/>
 <result pre="antihuman interleukin 6 (IL-6) receptor monoclonal antibody approved for the" exact="treatment" post="of rheumatoid arthritis and systemic juvenile idiopathic arthritis [60,"/>
 <result pre="no known effect on QTc interval Allergic reaction, susceptible to" exact="infection" post="62â€&quot;68 Â Â Interferon-Î²1 A cytokine produced by innate"/>
 <result pre="L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="M, Doudier B, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual" exact="screening" post="reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res."/>
 <result pre="KH, Chan KS, et al. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252â€&quot;6."/>
 <result pre="SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19" exact="treatment" post="option. J Med Virol. 2020;92:556â€&quot;63. 24.Cao B, Wang Y,"/>
 <result pre="Sci. 2017;93(7):449â€&quot;63. 32.Qingxian Caia MY, Liu D, et al. Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control study. Engineering."/>
 <result pre="Clinical study for safety and efficacy of Favipiravir in the" exact="treatment" post="of novel coronavirus pneumonia (COVID-19). 2020;ChiCTR2000029600. 34.Various Combination of"/>
 <result pre="Fan YP, et al. A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
 <result pre="et al. A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)."/>
 <result pre="MacLaren D, et al. Impact of ivermectin administered for scabies" exact="treatment" post="on the prevalence of head lice in Atoifi Solomon"/>
 <result pre="al. Impact of ivermectin administered for scabies treatment on the" exact="prevalence" post="of head lice in Atoifi Solomon Islands. PLoS Negl"/>
 <result pre="JM, Lammie PJ. Assessment of combined ivermectin and albendazole for" exact="treatment" post="of intestinal helminth and Wuchereria bancrofti infections in Haitian"/>
 <result pre="V, Vidal E, Bedane C. Systemic adverse reactions with ivermectin" exact="treatment" post="of scabies. Ann Dermatol Venereol. 2006;133(10):784â€&quot;7. 48.Goa KL, McTavish"/>
 <result pre="et al. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. 2005;2:69. 52.Liu J, Cao R,"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. 2020;6:16. 53.Sahraei Z, Shabani M,"/>
 <result pre="Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the" exact="treatment" post="of patients with rheumatoid arthritis. Ther Adv Musculoskelet Dis."/>
 <result pre="Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab" exact="treatment" post="in COVID-19: a single center experience. J Med Virol."/>
 <result pre="Peiffer-Smadja N, Committee CDFS. Type 1 interferons as a potential" exact="treatment" post="against COVID-19. Antivir Res. 2020;178:104791. 71.Sheahan TP, Sims AC,"/>
</results>
